ArticlePolish journal of radiology2022
The role of three different contrast-enhanced, abbreviated MRI protocols as a screening tool of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Article in Polish journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Our study aims to assess the role and diagnostic performance of 3 different contrast-enhanced, abbreviated magnetic resonance imaging (MRI) protocols as a screening tool of hepatocellular carcinoma (HCC). Material and methods: Our retrospective study included 80 patients who were screened for HCC: 47 patients revealed 138 focal hepatic lesions. MRI examinations were performed including full CE-MRI protocols. The MRI was done on a 1.5 T machine. Then 3 different abbreviated contrast-enhanced MRI protocols were analysed separately. The standard dynamic contrast MRI and abbreviated protocols were evaluated following the LI-RADS 2018 lexicon diagnostic features. Results: A considerable overall kappa (k) agreement between the abbreviated 1, 2, and 3 protocols on LI-RADS classification was noted with k = 0.865. There was almost perfect agreement between all abbreviated protocols and full standard protocol on LI-RADS classification, with k = 0.890. As regards the k agreement on LI-RADS classification, there was a considerable highest agreement between the abbreviated 1 protocol and the full standard protocol, with k = 0.980. The abbreviated 1 and 2 protocols showed high diagnostic performance on LI-RADS classification of lesions, with 100% sensitivity, specificity, PPV, NPV, and accuracy, while the abbreviated 3 protocol showed a lesser but comparable sensitivity 96.9%, NPV 99.4, and accuracy 99.4%. Conclusions: Abbreviated contrast-enhanced MRI protocols can be used as a screening tool for the detection of HCC, with high sensitivity, specificity, PPV, NPV, and accuracy close to the full protocol. There was a considerable highest agreement between the abbreviated 1 protocol and the full standard protocol. Subsequently, this protocol can be used as a standard protocol for screening high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.